Skip to main content

Table 2 Innovative and biosimilar drugs used to treat rheumatoid arthritis (RA), approved from 1998 to 2019, in the countries analyzed

From: Drug prices in Latin American countries: the case of rheumatoid arthritis Biosimilars

Drugs Registration year Country
Abatacept 2005 US
2007 Brazil
2012 Spain
2016 Mexico
2018 Colombia
Adalimumab 2002 US
2003 Brazil/Colombia
2010 Mexico
2018 Spain
Adalimumab 2018 Spain
Biosimilar 2019 Brazil/Colombia
  2015 US
Baricitinib 2017 Spain/Mexico
2018 US/Brazil
2019 Colombia
Certolizumabe pegol 2009 US
2011 Brazil
2016 Colombia
2017 Spain/Mexico
Etanercept 1999 Mexico
2002 US
2003 Brazil
2006 Spain
2007 Colombia
Etanercept biosimilar 2006 Colombia
2013 Brazil/Mexico
2016 US
  2017 Spain
Golimumab 2009 US
2011 Brazil/Colombia
2013 Spain
2014 Mexico
Infliximab 1999 Spain
2000 Colombia
2001 US
2007 Brazil
2016 Mexico
Infliximab 2014 Spain/Mexico
Biosimilar 2013 US
  2015 Brazil
  2017 Colombia
Rituximab 1998 Brazil/Spain
1999 Colombia
2006 US
2017 Mexico
Rituximab 2017 Spain/Mexico
Biosimilar 2019 Brazil
Tocilizumab 2009 Brazil/Mexico
2010 US
2014 Spain
2015 Colombia
Tofacitinib 2012 US
2013 Mexico
2014 Brazil
2018 Colombia/Spain